Next Science Limited announced that it has signed a multi-year distribution agreement for Australia and New Zealand with Oraderm Pharmaceuticals, a medical sales joint venture between Douglas Pharmaceuticals and Arrotex Pharmaceuticals, for the sale of Next Science's antimicrobial wound gel, BlastX. The new distribution agreement grants Oraderm exclusive rights across Australia and New Zealand for the sale and marketing of a dual Next Science /Oraderm labelled version of BlastX. Revenues arising from the agreement are based on an agreed unit price and a minimum quantity per order.

Next Science expects the revenues received from sales of BlastX to Oraderm to become material. The agreement term is 5 years and automatically extends for an additional period of 3 years subject to each party's termination rights. BlastX is an antimicrobial wound gel based on Next Science's patented, non-toxic, biofilm- disrupting Xbio technology.

BlastX deconstructs the bacterial biofilm, the gel envelops and eliminates the bacteria and then defends from recolonisation while maintaining a moist wound environment conducive to healing. The product is ideal for the treatment of non- healing wounds such as foot and leg ulcers and bed sores as well as preventing infections in acute wounds from trauma and surgical incision sites. BlastX can be used in hospital, pre- hospital, aged care and other clinical environments as well as in home care.

BlastX was cleared by the Australian Therapeutic Goods Administration in May 2021 allowing sales in Australia and New Zealand. The product has also received FDA 510(k) clearance and CE marking and is approved for sale in Canada. Oraderm's initial focus in Australia will be hospitals, nursing homes, dermatologists and over- the-counter pharmacy sales using Oraderm's own sales force.

In New Zealand, Oraderm will focus on wound care in hospitals and other clinical settings accommodating varied distribution solutions through Douglas Pharmaceuticals' sales team. Next Science is scheduled to deliver training to the Oraderm and Douglas Pharmaceuticals' sales force in late June with commercial sales in Australia and New Zealand expected to commence during second half of 2022. Chronic wounds continue to be a major health issue for patients across the global community.

They are often very difficult to treat, increase pain and suffering, cause a decline in quality of life, increase mortality and add considerable costs to healthcare systems and individuals. It is estimated that more than 400,000 people in Australia suffer from a chronic wound at any time.